Bio-arbitration

Bio-arbitration resolves patent, licensing, and commercial disputes between biotech and biopharmaceutical companies through arbitration and litigation rather than court trial, often involving settlements in the hundreds of millions to billions of dollars — a single 2026 settlement between Moderna and Arbutus/Genevant over mRNA lipid-nanoparticle patent rights closed at $2.25 billion. Unlike a dedicated “bio-arbitration” vendor category, this work is handled by the general intellectual-property litigation practices of a small number of elite law firms, for whom biotech patent disputes are one client vertical among several rather than a standalone specialty. As of 2026 only one firm was confirmed with strong, on-topic, own-domain evidence of an active biotech-specific arbitration/litigation practice; several other named candidates returned only weak or off-topic evidence, consistent with a field that is real but concentrated rather than a broad commercial vendor market.

The key directions of bio-arbitration are:

1. Patent settlement negotiation and litigation: representing a biotech or biopharma client through the full litigation-to-settlement cycle in a patent-infringement dispute, often running in parallel across multiple jurisdictions.
2. Licensing and royalty dispute resolution: resolving disputes over the terms, scope, or breach of a technology-licensing agreement between biotech partners.
3. International arbitration under institutional rules: disputes routed through bodies such as the ICC or AAA-ICDR rather than national courts, common in cross-border biotech partnerships.
4. Trade-secret and inventorship disputes: resolving disputes over who invented a given technology or whether confidential biotech know-how was misappropriated.

Sectoral value chain#

[Dispute arises] ──> [Pre-filing strategy] ──> [Litigation/arbitration filing] ──> [Discovery/evidence]
                                                          │
                                                (settlement negotiation)
                                                          │
                                                          ▼
[Resolution/settlement] <─── [Hearing/trial] <───────────┘

Value chain levels#

Cross-cutting technologies of the sector:

• Patent-portfolio analytics: tools for mapping the scope and validity risk of a biotech patent portfolio ahead of litigation.
• Technical expert coordination: managing the scientific expert testimony that is central to any biotech patent dispute.
• Cross-border enforcement mechanisms: the legal infrastructure for enforcing a settlement or award across multiple jurisdictions, common given biotech’s globally distributed manufacturing and licensing.

The category’s “technology” is primarily legal and analytical rather than a physical product — the tools that support a high-value biotech patent dispute rather than a marketed system.

1. Patent-portfolio and validity analysis:
   • Before filing, counsel maps the scope and validity risk of the relevant patent portfolio, a technical exercise requiring both legal and scientific expertise specific to the biotechnology at issue (in the Moderna-Arbutus case, mRNA lipid-nanoparticle delivery technology).
2. Multi-jurisdictional case coordination:
   • Major biotech patent disputes frequently run in parallel across multiple jurisdictions, requiring coordination between local counsel and the lead firm managing overall strategy.
3. Settlement structuring:
   • The $2.25 billion Moderna-Arbutus/Genevant settlement reflects the scale of value at stake in biotech IP disputes and the negotiation and structuring expertise required to resolve them without a full trial.